A large study suggests that pediatric cancer patients are more likely to die in the hospital than at home. The data showed that 52% of patients died in the hospital, and 40% died at home. These ...

SBRT and hypofractionated CRT produced similar outcomes in patients with inoperable stage I NSCLC in a phase 3 trial.

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Receiving an mRNA COVID-19 vaccine within 100 days of starting ICI therapy may improve overall survival in some cancer patients.

(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

Breastfeeding appears feasible and safe for breast cancer survivors with BRCA1/2 mutations or hormone receptor-positive disease ...

Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.

Credit: Science Source images Cabozantinib plus atezolizumab “may be useful” for selected patients with mCRPC whose disease progressed on hormone therapy, according to Neeraj Agarwal, MD.